Investment Rating - The report maintains a "Buy" rating for the company with a target price of 30.62 RMB [7]. Core Insights - The company achieved a revenue of 465 million RMB in 2025, with a year-over-year growth of 12.4%, while net profit attributable to the parent company was 51.08 million RMB, reflecting a slight decline of 1.9% [1][5]. - The gross margin for 2025 was reported at 57.98%, a decrease of 0.75 percentage points year-over-year, attributed to changes in product sales structure [1]. - The operating cash flow for 2025 improved significantly, reaching 90.90 million RMB, an increase of 35.0% year-over-year [1]. Revenue Growth and Product Performance - High-end catheter products generated 322 million RMB in revenue for 2025, marking a 7.5% increase, with notable performance from high-end products like the pressure ablation catheter [2]. - Equipment products saw a substantial revenue increase of 49.1%, totaling 39.44 million RMB, indicating growing market recognition [2]. - Other products, primarily sheath products, achieved 91 million RMB in revenue, up 12.6% year-over-year, with expectations for continued growth in 2026 [2]. International Business Expansion - The overseas revenue reached 165 million RMB in 2025, reflecting a robust growth of 46.5%, with Europe, the Middle East, Africa, and Latin America showing high growth rates [3]. - The overseas revenue proportion increased to 35.4%, up 8.2 percentage points year-over-year, driven by successful market expansions in Mexico, the UK, Tajikistan, and Colombia [3]. - Domestic revenue was 288 million RMB, down 2.3% year-over-year, primarily due to market pressures on non-high-end products [3]. New Product Development - The company successfully obtained domestic approvals for its PFA products and other high-end innovations in 2025, enhancing its product matrix in the electrophysiology treatment sector [4]. - The intracardiac ultrasound product received approval in early 2026, further strengthening the company's core product offerings [4]. - The RDN product is currently in clinical trials, with expectations for domestic approval in 2027 [4]. Profit Forecast and Valuation - The report adjusts the short-term profit forecast downward while raising long-term profit expectations, projecting net profits of 74.05 million RMB, 112.14 million RMB, and 166.81 million RMB for 2026, 2027, and 2028 respectively [5][11]. - The target price based on DCF analysis is set at 30.62 RMB, reflecting an increase from the previous estimate of 29.79 RMB [5][17].

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 31.18 [1][7]. Core Views - The company achieved revenue of RMB 224 million in 1H25, representing a year-on-year increase of 12.8%, and a net profit of RMB 32.67 million, up 92.0% year-on-year, aligning with performance expectations [1]. - The gross margin for 1H25 was 60.1%, an increase of 1.0 percentage points year-on-year, driven by the strong performance of high-end products [1]. - The company is expected to see rapid growth in overall performance in 2025 due to continuous improvement in its product matrix and active overseas sales efforts [1]. Revenue Breakdown - Catheter products generated revenue of RMB 161 million, with high-end catheter products showing rapid growth, completing over 3,000 surgeries in China by 1H25 [2]. - Equipment products contributed RMB 16.19 million, with expectations for positive development in 2025 amid recovering industry demand [2]. - Other products, mainly sheath products, achieved revenue of RMB 45.25 million, expected to grow alongside the overall increase in surgical volumes [2]. Overseas Expansion - Overseas revenue reached RMB 69.47 million, a year-on-year increase of over 40%, accounting for 31% of total revenue [3]. - The company has made significant progress in overseas commercialization, with three-dimensional surgeries implemented in over 20 countries by 1H25 [3]. - Domestic revenue was RMB 154 million, with expectations for growth driven by the release of high-end products [3]. Product Development - The company is making progress in new product development, including PFA products and intracardiac ultrasound, with expectations for domestic approval in 2025 and 2026, respectively [4]. - The RDN product is currently in clinical trials, with anticipated domestic approval in 2026 [4]. Profit Forecast and Valuation - The profit forecast has been adjusted, with expected net profits for 2025-2027 at RMB 84 million, RMB 118 million, and RMB 162 million, respectively, reflecting increases of 18%, 7%, and 1% compared to previous estimates [5]. - Using DCF valuation methods, the target price is set at RMB 31.18, up from a previous estimate of RMB 27.73 [5][17].